'Svr 12' diaporamas de présentation

Best of HCV From AASLD 2013

Best of HCV From AASLD 2013. Kimberly A. Brown, MD Detroit, Michigan, USA. This activity has been supported by an independent medical education grant from Bristol Myers Squibb .

683 views • 61 slides

Best of HCV From AASLD 2013

Best of HCV From AASLD 2013. Paul Kwo , MD Indianapolis, Indiana, USA. This activity has been supported by an independent medical education grant from Bristol Myers Squibb.

654 views • 54 slides

Best of HCV From AASLD 2013

Best of HCV From AASLD 2013. Darrell Crawford, MD Brisbane, Australia. This activity has been supported by an independent medical education grant from Bristol Myers Squibb.

507 views • 42 slides

N = 75

366 views • 9 slides

QUEST-2 Study : SMV + PEG-IFN + RBV for genotype 1

255 views • 8 slides

FUSION Study : SOF + RBV (12 vs 16 weeks) for HCV genotypes 2 and 3

FUSION Study : SOF + RBV (12 vs 16 weeks) for HCV genotypes 2 and 3. Design. Randomisation 1 : 1* Blinded, active-control. W12. W16. W24. W28. HCV genotype 2 or 3 No response to prior treatment with IFN-based regimen HCV RNA ? 10,000 IU/ml Compensated cirrhosis allowed. N = 103.

64 views • 6 slides

IMPACT S tudy : SMV + DCV + SOF in HCV genotype 1 with decompensated liver disease

65 views • 6 slides

Treatment regimens

57 views • 5 slides

Japanese SOF + RBV Study : SOF + RBV in genotype 2

60 views • 5 slides